NASDAQ
Cullinan Therapeutics, Inc. (CGEM) has a free cash flow growth of -20.79% as of Friday, May 29, 2026. This represents a 345.60% decrease compared to its 12-month average of -4.67%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.